Online citations, reference lists, and bibliographies.

Survival Prognostic Factors In Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery And Intraoperative Hyperthermic Intraperitoneal Chemotherapy: A Single Institution Experience.

Srdjan Nikolić, Radan Džodić, Milan Žegarac, Igor Djurisić, Dušica Gavrilović, V. Culafic Vojinovic, M Gordana Kocić, N. S. Santrac, Petar Radlović, Davorin Radosavljević, Gordana Pupić, Aleksandar Martinović
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE The aim of this research was to examine overall (OS) and disease-free survival (DFS) in patients with colorectal peritoneal carcinomatosis (CRC-PC), treated with cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), as well as to analyse factors of prognostic significance. METHODS We included 61 patients with pathological/and computerized tomography (CT) confirmation of CRC-PC, treated with CRS+HIPEC from 2005 to 2012. Peritoneal Cancer Index (PCI) score was used for quantitative assessment of the CRC-PC extent. We performed CRS following the Sugarbaker's principles in all patients with PCI ≤20 and only in 3/61 (4.92%) patients with PCI >20. HIPEC (oxaliplatin 410 mg/m(2) in 2000mL isotonic solution and 41?C) was performed using RanD Performer® HT perfusion system during 30-60 min. Cox proportional hazard regression was used to determine significant factors for OS and DFS. RESULTS The follow-up ranged from 1 to 83 months (median 22). Median OS was 51 months (95% confidence interval/ CI 22+). Median DFS for patients without residual disease (57/61, 93.44%) was 23 months (95% CI 16+). One-, 2- and 6-year OS (DFS) were 78.6% (68.3%), 58.7% (46.7%) and 50.5% (38.1%), respectively. By the end of the study, 55.74% of the patients were still alive. Cox multivariate analysis indicated PCI score as a parameter of highly prognostic significance for patients treated with CRS+HIPEC (p<0.001). Patients with PCI (13 (vs PCI ≥13) had significantly longer OS and DFS (p<0.001), also confirmed for PCI subcategories (PCI <7 vs 7≤ PCI <13 vs PCI ≥13). All patients with PCI <7 are still alive. CONCLUSION Our study indicates that CRS+HIPEC significantly improves the survival of CRC-PC patients. This treatment modality should be considered as the most suitable in well-selected patients with this disease.
This paper references
10.1097/PPO.0b013e3181a58d56
Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy: The Importance of a Learning Curve
Faheez Mohamed (2009)
10.1002/cncr.25116
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.
Jan Franko (2010)
10.1245/s10434-008-0105-x
Multivisceral Resection Does Not Affect Morbidity and Survival After Cytoreductive Surgery and Chemoperfusion for Carcinomatosis from Colorectal Cancer
Jan Franko (2008)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
Vic J. Verwaal (2003)
10.1200/JCO.2004.10.012
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Olivier Glehen (2004)
10.1245/s10434-012-2264-z
The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study
Daphne Hompes (2012)
10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V
Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.
David Z. J. Chu (1989)
10.4321/S1130-01082005001000005
Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update.
A. Gómez Portilla (2005)
10.1016/j.ejso.2012.01.001
Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery).
D. Elias (2012)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.
J. Esquivel (2007)
10.1200/JCO.2009.23.9285
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
Dominique M Elias (2010)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.
John D. Spiliotis (2008)
10.1016/S1470-2045(04)01425-1
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.
O. Glehen (2004)
Current indications for cytoreductive surgery and intraperitoneal chemotherapy
PH Sugarbaker (1998)
10.1245/s10434-008-9966-2
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
Vic J. Verwaal (2008)
10.1016/S1055-3207(03)00051-6
Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.
D. Elias (2003)
10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.
B Sadeghi (2000)
10.1016/S1470-2045(12)70210-3
Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?
Paul H Sugarbaker (2012)
10.4251/wjgo.v2.i2.98
Peritoneal carcinomatosis of colorectal origin.
A. Macrì (2010)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
P. Sugarbaker (1996)
10.1016/S1055-3207(03)00047-4
Management of peritoneal surface malignancy
Paul H Sugarbaker (2003)
toreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer : a multiinstitutional study
O Glehen (2004)
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
10.1016/j.ejso.2010.10.014
Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.
F. Cavaliere (2011)
10.1097/SLA.0b013e3181a45d86
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality
T. Chua (2009)
10.1002/jso.21057
Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy.
Rami J Younan (2008)
10.1016/j.ejso.2009.02.010
Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools.
Hendrik Albert Maurits Swellengrebel (2009)
10.1007/s00384-003-0524-x
Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities
Christian Knorr (2003)
Peritoneal carcinomatosis 2011; it's about time for chemosurgery.
John D. Spiliotis (2011)
10.1046/j.1365-2168.2002.02274.x
Peritoneal carcinomatosis from colorectal cancer.
D. Jayne (2002)



This paper is referenced by
10.1007/s11888-019-00427-1
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future
Craig Joshua Follette (2019)
10.3390/jcm7120567
Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer
Can Yurttas (2018)
Goblet cell carcinoid of the appendix. Review of the literature a propos of a rare case of endometrial metastases.
Milan Žegarac (2018)
10.18632/oncotarget.17497
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.
Chao-qun Huang (2017)
10.1007/s10147-017-1092-3
Preoperative platelet–lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
T. H. Bong (2017)
10.1186/s12885-019-5408-8
Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial
Vivian P Bastiaenen (2019)
10.1016/j.critrevonc.2016.01.017
Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review.
Dario Baratti (2016)
10.1016/j.critrevonc.2017.03.028
Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.
K. Rovers (2017)
Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience.
M Gordana Kocić (2016)
Management of peritoneal surface malignancy: a review of the recent literature.
Evgenia Halkia (2014)
10.1016/j.ejso.2015.05.018
Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review.
T. V. van Oudheusden (2015)
Semantic Scholar Logo Some data provided by SemanticScholar